All the news articles and press releases in one place.

Date / Time Source Company Sector Market Cap Announcement
28Jul22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Chair’s Investor Update
26Jul22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Publication of new data on NTCD-M3
19Jul22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Positive update from US FDA on XF-73 Phase 3
12Jul22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Grant from the Cystic Fibrosis Foundation
07Jul22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Publication of XF-73 drug synergy data
05Jul22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - New XF-73 research programme
08Jun22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Grant of share options
27May22 11:56 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Result of Annual General Meeting & Strategy Update
26May22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Board Changes
12May22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Landmark NTCD-M3 data to be presented at Anaerobe
03May22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Destiny Pharma appoints Dr Yuri Martina as CMO
27Apr22 15:34 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Posting of Annual Report and Notice of AGM
26Apr22 15:30 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Director/PDMR Shareholding
12Apr22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Audited results for year ended 31 December 2021
04Apr22 14:45 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Notice of Results
04Apr22 14:37 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Notification of Major Holdings
31Mar22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - To present data at ECCMID Congress
28Mar22 11:30 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Result of General Meeting and Total Voting Rights
25Mar22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Result of Open Offer
22Mar22 10:30 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Exercise of Options and Total Voting Rights
08Mar22 12:30 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Fundraising
08Feb22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Positive feedback from EMA on XF-73 Nasal gel Ph 3
01Feb22 16:11 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Exercise of Options and Total Voting Rights
01Feb22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Positive data in XF-73 Dermal study with NIAID
31Jan22 14:30 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Exercise of Options and Total Voting Rights
25Jan22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Grant of share options
24Jan22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Clinical and commercial opportunity of NTCD-M3
21Jan22 07:15 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Destiny Pharma Lancet Report
17Jan22 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Strategy/Company/Ops Update
21Dec21 16:35 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Exercise of Options and Total Voting Rights
17Dec21 09:46 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Grant of share options
15Nov21 14:26 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Directorate Change
04Nov21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - SAB Member Prof. Gerding is Keynote at C.diff Conf
18Oct21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Study gives strong support for potential of XF-73
27Sep21 15:18 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Director/PDMR Shareholding
27Sep21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Expansion of clinical pipeline
09Sep21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Interim results for six months ended 30 June 2021
23Aug21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Notice of Interim Results
02Aug21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Secondary endpoint analysis from Phase 2b trial
09Jul21 08:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - XF-73 Phase 2b data to be presented at ECCMID
06Jul21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - NTCD-M3 RD Agreement with US Dept Veterans Affairs
02Jul21 08:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Scientific Advisor Gerding chairs C Diff symposium
29Jun21 08:24 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - DEST to present at Shares & AJ Bell Webinar 6/7/21
10Jun21 17:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Director Dealing
10Jun21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - XF-73 data abstract to be presented at 2021 ECCMID
07Jun21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Destiny Pharma welcomes G7’s Communique on AMR
03Jun21 12:03 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Result of AGM
02Jun21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Positive update on microbiome therapeutic NTCD-M3
25May21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Further information re AGM
19May21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma PLC - Notice to Register for 2021 AGM
06May21 10:00 RNS-R Destiny Pharma Plc Health £29.3m Conference Attendance for May 2021
04May21 07:00 RNS Destiny Pharma Plc Health £29.3m Posting of Annual Report and Notice of AGM
30Apr21 07:00 RNS Destiny Pharma Plc Health £29.3m Director Dealing
23Apr21 07:00 RNS Destiny Pharma Plc Health £29.3m Director Dealing
15Apr21 08:00 RNS-R Destiny Pharma Plc Health £29.3m FY 2020 Investor Presentation
14Apr21 07:00 RNS Destiny Pharma Plc Health £29.3m Final Results
29Mar21 12:45 RNS Destiny Pharma Plc Health £29.3m Exercise of Options and Total Voting Rights
29Mar21 12:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma to Join Equity Development Webinar
29Mar21 10:15 RNS Destiny Pharma Plc Health £29.3m Exercise of Options and Total Voting Rights
29Mar21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma Reports Positive Phase 2b Results
16Mar21 07:00 RNS Destiny Pharma Plc Health £29.3m Notice of Results
15Mar21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma Announces Agreement with NIAID
10Mar21 14:15 RNS Destiny Pharma Plc Health £29.3m Exercise of Options and Total Voting Rights
10Mar21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma CSO Joins UKRI COVID-19 Taskforce
03Feb21 07:00 RNS Destiny Pharma Plc Health £29.3m Brazilian Patent Granted for XF-73 nasal gel
02Feb21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma Appoints Professor Mark Wilcox
21Jan21 16:31 RNS Destiny Pharma Plc Health £29.3m Grant of Share Options
21Jan21 08:28 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma Investor Presentation
07Jan21 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny Pharma: Directors Dealings
06Jan21 08:00 RNS-R Destiny Pharma Plc Health £29.3m Destiny Pharma Appoints Stephanie Bewick as CBO
05Jan21 07:00 RNS Destiny Pharma Plc Health £29.3m Phase 2b trial of XF-73 completes recruitment
23Dec20 14:09 RNS Destiny Pharma Plc Health £29.3m Grant of share options
22Dec20 07:00 RNS Destiny Pharma Plc Health £29.3m Update on the recently acquired NTCD-M3 programme
01Dec20 17:23 RNS Destiny Pharma Plc Health £29.3m Holding(s) in Company
30Nov20 14:00 RNS Destiny Pharma Plc Health £29.3m Holding(s) in Company
26Nov20 10:50 RNS Destiny Pharma Plc Health £29.3m Result of General Meeting and Total Voting Rights
25Nov20 07:00 RNS Destiny Pharma Plc Health £29.3m Result of Open Offer
09Nov20 16:25 RNS Destiny Pharma Plc Health £29.3m Fundraising and Acquisition
12Oct20 07:00 RNS Destiny Pharma Plc Health £29.3m Clinical Study Patient Recruitment Update
17Sep20 07:00 RNS Destiny Pharma Plc Health £29.3m Update on Phase 2b clinical study of XF-73
17Sep20 07:00 RNS Destiny Pharma Plc Health £29.3m Interim results for the 6 months ended 30 Jun 2020
10Sep20 07:00 RNS Destiny Pharma Plc Health £29.3m Notice of Results
07Sep20 07:00 RNS Destiny Pharma Plc Health £29.3m Collaboration to co-develop treatment for COVID-19
11Aug20 07:00 RNS Destiny Pharma Plc Health £29.3m Positive interim safety review of XF-73 phase 2b
27Jul20 07:00 RNS Destiny Pharma Plc Health £29.3m Update on Phase 2b clinical study of XF-73
15Jul20 07:00 RNS-R Destiny Pharma Plc Health £29.3m Destiny Pharma notes launch of AMR Action Fund
19Jun20 11:00 RNS Destiny Pharma Plc Health £29.3m Cancellation and Grant of Options
10Jun20 12:30 RNS Destiny Pharma Plc Health £29.3m Result of AGM
09Jun20 07:00 RNS Destiny Pharma Plc Health £29.3m Grant awarded for Cardiff University collaboration
12May20 15:15 RNS Destiny Pharma Plc Health £29.3m Posting of Annual Report and Notice of AGM
04May20 07:00 RNS Destiny Pharma Plc Health £29.3m Independent review supports the potential of XF-73
29Apr20 07:00 RNS Destiny Pharma Plc Health £29.3m Final Results
24Apr20 07:00 RNS Destiny Pharma Plc Health £29.3m Notice of Results
03Mar20 07:00 RNS Destiny Pharma Plc Health £29.3m Clinical and Business Update
20Jan20 07:00 RNS-R Destiny Pharma Plc Health £29.3m Update on the development of XF drug formulations
17Dec19 07:00 RNS-R Destiny Pharma Plc Health £29.3m APSIC guidelines recommend decolonising S. aureus
02Dec19 07:00 RNS Destiny Pharma Plc Health £29.3m Directorate Change
02Dec19 07:00 RNS Destiny Pharma Plc Health £29.3m Destiny to present at UK-China AMR Workshop
15Nov19 07:30 RNS-R Destiny Pharma Plc Health £29.3m Presentation at the Investival Showcase
06Nov19 07:00 RNS-R Destiny Pharma Plc Health £29.3m Destiny Pharma to present at World AMR Congress
Date / Time Source Company % Chg
28Jul22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Chair’s Investor Update
26Jul22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Publication of new data on NTCD-M3
19Jul22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Positive update from US FDA on XF-73 Phase 3
12Jul22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Grant from the Cystic Fibrosis Foundation
07Jul22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Publication of XF-73 drug synergy data
05Jul22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - New XF-73 research programme
08Jun22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Grant of share options
27May22 11:56 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Result of Annual General Meeting & Strategy Update
26May22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Board Changes
12May22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Landmark NTCD-M3 data to be presented at Anaerobe
03May22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Destiny Pharma appoints Dr Yuri Martina as CMO
27Apr22 15:34 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Posting of Annual Report and Notice of AGM
26Apr22 15:30 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Director/PDMR Shareholding
12Apr22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Audited results for year ended 31 December 2021
04Apr22 14:45 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Notice of Results
04Apr22 14:37 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Notification of Major Holdings
31Mar22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - To present data at ECCMID Congress
28Mar22 11:30 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Result of General Meeting and Total Voting Rights
25Mar22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Result of Open Offer
22Mar22 10:30 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
08Mar22 12:30 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Fundraising
08Feb22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Positive feedback from EMA on XF-73 Nasal gel Ph 3
01Feb22 16:11 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
01Feb22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Positive data in XF-73 Dermal study with NIAID
31Jan22 14:30 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
25Jan22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Grant of share options
24Jan22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Clinical and commercial opportunity of NTCD-M3
21Jan22 07:15 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Destiny Pharma Lancet Report
17Jan22 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Strategy/Company/Ops Update
21Dec21 16:35 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
17Dec21 09:46 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Grant of share options
15Nov21 14:26 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Directorate Change
04Nov21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - SAB Member Prof. Gerding is Keynote at C.diff Conf
18Oct21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Study gives strong support for potential of XF-73
27Sep21 15:18 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Director/PDMR Shareholding
27Sep21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Expansion of clinical pipeline
09Sep21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Interim results for six months ended 30 June 2021
23Aug21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Notice of Interim Results
02Aug21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Secondary endpoint analysis from Phase 2b trial
09Jul21 08:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - XF-73 Phase 2b data to be presented at ECCMID
06Jul21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - NTCD-M3 RD Agreement with US Dept Veterans Affairs
02Jul21 08:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Scientific Advisor Gerding chairs C Diff symposium
29Jun21 08:24 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - DEST to present at Shares & AJ Bell Webinar 6/7/21
10Jun21 17:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Director Dealing
10Jun21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - XF-73 data abstract to be presented at 2021 ECCMID
07Jun21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Destiny Pharma welcomes G7’s Communique on AMR
03Jun21 12:03 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Result of AGM
02Jun21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Positive update on microbiome therapeutic NTCD-M3
25May21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Further information re AGM
19May21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Notice to Register for 2021 AGM
06May21 10:00 RNS-R Destiny Pharma Plc 0.00%
Conference Attendance for May 2021
04May21 07:00 RNS Destiny Pharma Plc 0.00%
Posting of Annual Report and Notice of AGM
30Apr21 07:00 RNS Destiny Pharma Plc 0.00%
Director Dealing
23Apr21 07:00 RNS Destiny Pharma Plc 0.00%
Director Dealing
15Apr21 08:00 RNS-R Destiny Pharma Plc 0.00%
FY 2020 Investor Presentation
14Apr21 07:00 RNS Destiny Pharma Plc 0.00%
Final Results
29Mar21 12:45 RNS Destiny Pharma Plc 0.00%
Exercise of Options and Total Voting Rights
29Mar21 12:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma to Join Equity Development Webinar
29Mar21 10:15 RNS Destiny Pharma Plc 0.00%
Exercise of Options and Total Voting Rights
29Mar21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma Reports Positive Phase 2b Results
16Mar21 07:00 RNS Destiny Pharma Plc 0.00%
Notice of Results
15Mar21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma Announces Agreement with NIAID
10Mar21 14:15 RNS Destiny Pharma Plc 0.00%
Exercise of Options and Total Voting Rights
10Mar21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma CSO Joins UKRI COVID-19 Taskforce
03Feb21 07:00 RNS Destiny Pharma Plc 0.00%
Brazilian Patent Granted for XF-73 nasal gel
02Feb21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma Appoints Professor Mark Wilcox
21Jan21 16:31 RNS Destiny Pharma Plc 0.00%
Grant of Share Options
21Jan21 08:28 RNS Destiny Pharma Plc 0.00%
Destiny Pharma Investor Presentation
07Jan21 07:00 RNS Destiny Pharma Plc 0.00%
Destiny Pharma: Directors Dealings
06Jan21 08:00 RNS-R Destiny Pharma Plc 0.00%
Destiny Pharma Appoints Stephanie Bewick as CBO
05Jan21 07:00 RNS Destiny Pharma Plc 0.00%
Phase 2b trial of XF-73 completes recruitment
23Dec20 14:09 RNS Destiny Pharma Plc 0.00%
Grant of share options
22Dec20 07:00 RNS Destiny Pharma Plc 0.00%
Update on the recently acquired NTCD-M3 programme
01Dec20 17:23 RNS Destiny Pharma Plc 0.00%
Holding(s) in Company
30Nov20 14:00 RNS Destiny Pharma Plc 0.00%
Holding(s) in Company
26Nov20 10:50 RNS Destiny Pharma Plc 0.00%
Result of General Meeting and Total Voting Rights
25Nov20 07:00 RNS Destiny Pharma Plc 0.00%
Result of Open Offer
09Nov20 16:25 RNS Destiny Pharma Plc 0.00%
Fundraising and Acquisition
12Oct20 07:00 RNS Destiny Pharma Plc 0.00%
Clinical Study Patient Recruitment Update
17Sep20 07:00 RNS Destiny Pharma Plc 0.00%
Update on Phase 2b clinical study of XF-73
17Sep20 07:00 RNS Destiny Pharma Plc 0.00%
Interim results for the 6 months ended 30 Jun 2020
10Sep20 07:00 RNS Destiny Pharma Plc 0.00%
Notice of Results
07Sep20 07:00 RNS Destiny Pharma Plc 0.00%
Collaboration to co-develop treatment for COVID-19
11Aug20 07:00 RNS Destiny Pharma Plc 0.00%
Positive interim safety review of XF-73 phase 2b
27Jul20 07:00 RNS Destiny Pharma Plc 0.00%
Update on Phase 2b clinical study of XF-73
15Jul20 07:00 RNS-R Destiny Pharma Plc 0.00%
Destiny Pharma notes launch of AMR Action Fund
19Jun20 11:00 RNS Destiny Pharma Plc 0.00%
Cancellation and Grant of Options
10Jun20 12:30 RNS Destiny Pharma Plc 0.00%
Result of AGM
09Jun20 07:00 RNS Destiny Pharma Plc 0.00%
Grant awarded for Cardiff University collaboration
12May20 15:15 RNS Destiny Pharma Plc 0.00%
Posting of Annual Report and Notice of AGM
04May20 07:00 RNS Destiny Pharma Plc 0.00%
Independent review supports the potential of XF-73
29Apr20 07:00 RNS Destiny Pharma Plc 0.00%
Final Results
24Apr20 07:00 RNS Destiny Pharma Plc 0.00%
Notice of Results
03Mar20 07:00 RNS Destiny Pharma Plc 0.00%
Clinical and Business Update
20Jan20 07:00 RNS-R Destiny Pharma Plc 0.00%
Update on the development of XF drug formulations
17Dec19 07:00 RNS-R Destiny Pharma Plc 0.00%
APSIC guidelines recommend decolonising S. aureus
02Dec19 07:00 RNS Destiny Pharma Plc 0.00%
Directorate Change
02Dec19 07:00 RNS Destiny Pharma Plc 0.00%
Destiny to present at UK-China AMR Workshop
15Nov19 07:30 RNS-R Destiny Pharma Plc 0.00%
Presentation at the Investival Showcase
06Nov19 07:00 RNS-R Destiny Pharma Plc 0.00%
Destiny Pharma to present at World AMR Congress
Date / Time Company % Chg
28Jul22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Chair’s Investor Update
26Jul22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Publication of new data on NTCD-M3
19Jul22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Positive update from US FDA on XF-73 Phase 3
12Jul22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Grant from the Cystic Fibrosis Foundation
07Jul22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Publication of XF-73 drug synergy data
05Jul22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - New XF-73 research programme
08Jun22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Grant of share options
27May22 11:56 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Result of Annual General Meeting & Strategy Update
26May22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Board Changes
12May22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Landmark NTCD-M3 data to be presented at Anaerobe
03May22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Destiny Pharma appoints Dr Yuri Martina as CMO
27Apr22 15:34 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Posting of Annual Report and Notice of AGM
26Apr22 15:30 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Director/PDMR Shareholding
12Apr22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Audited results for year ended 31 December 2021
04Apr22 14:45 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Notice of Results
04Apr22 14:37 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Notification of Major Holdings
31Mar22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - To present data at ECCMID Congress
28Mar22 11:30 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Result of General Meeting and Total Voting Rights
25Mar22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Result of Open Offer
22Mar22 10:30 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
08Mar22 12:30 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Fundraising
08Feb22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Positive feedback from EMA on XF-73 Nasal gel Ph 3
01Feb22 16:11 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
01Feb22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Positive data in XF-73 Dermal study with NIAID
31Jan22 14:30 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
25Jan22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Grant of share options
24Jan22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Clinical and commercial opportunity of NTCD-M3
21Jan22 07:15 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Destiny Pharma Lancet Report
17Jan22 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Strategy/Company/Ops Update
21Dec21 16:35 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Exercise of Options and Total Voting Rights
17Dec21 09:46 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Grant of share options
15Nov21 14:26 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Directorate Change
04Nov21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - SAB Member Prof. Gerding is Keynote at C.diff Conf
18Oct21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Study gives strong support for potential of XF-73
27Sep21 15:18 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Director/PDMR Shareholding
27Sep21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Expansion of clinical pipeline
09Sep21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Interim results for six months ended 30 June 2021
23Aug21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Notice of Interim Results
02Aug21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Secondary endpoint analysis from Phase 2b trial
09Jul21 08:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - XF-73 Phase 2b data to be presented at ECCMID
06Jul21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - NTCD-M3 RD Agreement with US Dept Veterans Affairs
02Jul21 08:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Scientific Advisor Gerding chairs C Diff symposium
29Jun21 08:24 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - DEST to present at Shares & AJ Bell Webinar 6/7/21
10Jun21 17:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Director Dealing
10Jun21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - XF-73 data abstract to be presented at 2021 ECCMID
07Jun21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Destiny Pharma welcomes G7’s Communique on AMR
03Jun21 12:03 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Result of AGM
02Jun21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Positive update on microbiome therapeutic NTCD-M3
25May21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Further information re AGM
19May21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma PLC - Notice to Register for 2021 AGM
06May21 10:00 Destiny Pharma Plc 0.00%
Conference Attendance for May 2021
04May21 07:00 Destiny Pharma Plc 0.00%
Posting of Annual Report and Notice of AGM
30Apr21 07:00 Destiny Pharma Plc 0.00%
Director Dealing
23Apr21 07:00 Destiny Pharma Plc 0.00%
Director Dealing
15Apr21 08:00 Destiny Pharma Plc 0.00%
FY 2020 Investor Presentation
14Apr21 07:00 Destiny Pharma Plc 0.00%
Final Results
29Mar21 12:45 Destiny Pharma Plc 0.00%
Exercise of Options and Total Voting Rights
29Mar21 12:00 Destiny Pharma Plc 0.00%
Destiny Pharma to Join Equity Development Webinar
29Mar21 10:15 Destiny Pharma Plc 0.00%
Exercise of Options and Total Voting Rights
29Mar21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma Reports Positive Phase 2b Results
16Mar21 07:00 Destiny Pharma Plc 0.00%
Notice of Results
15Mar21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma Announces Agreement with NIAID
10Mar21 14:15 Destiny Pharma Plc 0.00%
Exercise of Options and Total Voting Rights
10Mar21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma CSO Joins UKRI COVID-19 Taskforce
03Feb21 07:00 Destiny Pharma Plc 0.00%
Brazilian Patent Granted for XF-73 nasal gel
02Feb21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma Appoints Professor Mark Wilcox
21Jan21 16:31 Destiny Pharma Plc 0.00%
Grant of Share Options
21Jan21 08:28 Destiny Pharma Plc 0.00%
Destiny Pharma Investor Presentation
07Jan21 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma: Directors Dealings
06Jan21 08:00 Destiny Pharma Plc 0.00%
Destiny Pharma Appoints Stephanie Bewick as CBO
05Jan21 07:00 Destiny Pharma Plc 0.00%
Phase 2b trial of XF-73 completes recruitment
23Dec20 14:09 Destiny Pharma Plc 0.00%
Grant of share options
22Dec20 07:00 Destiny Pharma Plc 0.00%
Update on the recently acquired NTCD-M3 programme
01Dec20 17:23 Destiny Pharma Plc 0.00%
Holding(s) in Company
30Nov20 14:00 Destiny Pharma Plc 0.00%
Holding(s) in Company
26Nov20 10:50 Destiny Pharma Plc 0.00%
Result of General Meeting and Total Voting Rights
25Nov20 07:00 Destiny Pharma Plc 0.00%
Result of Open Offer
09Nov20 16:25 Destiny Pharma Plc 0.00%
Fundraising and Acquisition
12Oct20 07:00 Destiny Pharma Plc 0.00%
Clinical Study Patient Recruitment Update
17Sep20 07:00 Destiny Pharma Plc 0.00%
Update on Phase 2b clinical study of XF-73
17Sep20 07:00 Destiny Pharma Plc 0.00%
Interim results for the 6 months ended 30 Jun 2020
10Sep20 07:00 Destiny Pharma Plc 0.00%
Notice of Results
07Sep20 07:00 Destiny Pharma Plc 0.00%
Collaboration to co-develop treatment for COVID-19
11Aug20 07:00 Destiny Pharma Plc 0.00%
Positive interim safety review of XF-73 phase 2b
27Jul20 07:00 Destiny Pharma Plc 0.00%
Update on Phase 2b clinical study of XF-73
15Jul20 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma notes launch of AMR Action Fund
19Jun20 11:00 Destiny Pharma Plc 0.00%
Cancellation and Grant of Options
10Jun20 12:30 Destiny Pharma Plc 0.00%
Result of AGM
09Jun20 07:00 Destiny Pharma Plc 0.00%
Grant awarded for Cardiff University collaboration
12May20 15:15 Destiny Pharma Plc 0.00%
Posting of Annual Report and Notice of AGM
04May20 07:00 Destiny Pharma Plc 0.00%
Independent review supports the potential of XF-73
29Apr20 07:00 Destiny Pharma Plc 0.00%
Final Results
24Apr20 07:00 Destiny Pharma Plc 0.00%
Notice of Results
03Mar20 07:00 Destiny Pharma Plc 0.00%
Clinical and Business Update
20Jan20 07:00 Destiny Pharma Plc 0.00%
Update on the development of XF drug formulations
17Dec19 07:00 Destiny Pharma Plc 0.00%
APSIC guidelines recommend decolonising S. aureus
02Dec19 07:00 Destiny Pharma Plc 0.00%
Directorate Change
02Dec19 07:00 Destiny Pharma Plc 0.00%
Destiny to present at UK-China AMR Workshop
15Nov19 07:30 Destiny Pharma Plc 0.00%
Presentation at the Investival Showcase
06Nov19 07:00 Destiny Pharma Plc 0.00%
Destiny Pharma to present at World AMR Congress